Skip to main
MDXG

MiMedx Group (MDXG) Stock Forecast & Price Target

MiMedx Group (MDXG) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MiMedx Group is a pioneering leader in the development and marketing of regenerative biomaterial products derived from human amniotic tissue, birth tissue, and human skin and bone. Despite headwinds caused by changes in Medicare wound reimbursement and confusion in the industry, MiMedx remains well-positioned for long-term success, with potential for double-digit revenue growth due to its strong product portfolio, ongoing research and development efforts, and expanding presence in the wound care and surgical markets. However, there are potential risks related to tissue donorship, the competitive nature of 361 regulated products, and contracts with group purchasing organizations and integrated delivery networks that could impact the company's future business.

Bears say

MiMedx Group is facing challenges in the form of reimbursement disruptions and a slow recovery in its Wound Care segment, which make it difficult to predict future revenue growth. While the company is making efforts to reduce costs and capitalize on growth opportunities, the stock may continue to underperform in the near term due to these challenges. Additionally, the uncertainty surrounding the impact of the Medicare outpatient ASP caps could further hamper the company's revenue growth in the coming years.

MiMedx Group (MDXG) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiMedx Group and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiMedx Group (MDXG) Forecast

Analysts have given MiMedx Group (MDXG) a Buy based on their latest research and market trends.

According to 5 analysts, MiMedx Group (MDXG) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiMedx Group (MDXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.